Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease in mice

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 3, 2017, Pages 708-715

  Jin, Cheng Jun ^a   Engstler, Anna Janina ^a   Ziegenhardt, Doreen ^a   Bischoff, Stephan C ^b   Trautwein, Christian ^c   Bergheim, Ina ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF HOHENHEIM   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

endotoxin; iNOS; LBP; NAFLD

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; ENDOTOXIN; FATTY ACID SYNTHASE; FRUCTOSE; GLUCOSE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TOLL LIKE RECEPTOR 4; ACUTE PHASE PROTEIN; CARRIER PROTEIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE INACTIVATION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LIPID PEROXIDATION; LIVER CELL CULTURE; LIVER HISTOLOGY; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DEFICIENCY; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY;

ACUTE-PHASE PROTEINS; ANIMALS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; GLUCOSE; LIPID METABOLISM; LIPOPOLYSACCHARIDES; LIVER; MEMBRANE GLYCOPROTEINS; MICE, INBRED BALB C; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 85015849374     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13488     Document Type: Article

References (41)

1. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J. Dig. Dis. 2015; 16: 541–557.
2. Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: current concepts and remaining challenges. Hepatol. Res. 2015; 45: 20–28.
3. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 2010; 5: 145–171.
4. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J. Endocrinol. 2013; 218: R25–R36.
5. Oliveira CP, de Lima SP, de Abreu-Silva EO, Marcadenti A. Nutrition and physical activity in nonalcoholic fatty liver disease. J. Diabetes Res. 2016; 2016: 4597246.
6. Kanuri G, Ladurner R, Skibovskaya J et al. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2015; 35: 562–568.
7. Thuy S, Ladurner R, Volynets V et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J. Nutr. 2008; 138: 1452–1455.
8. Vespasiani-Gentilucci U, Carotti S, Perrone G et al. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int. 2015; 35: 569–581.
9. Ruiz AG, Casafont F, Crespo J et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 2007; 17: 1374–1380.
10. Ding PH, Jin LJ. The role of lipopolysaccharide-binding protein in innate immunity: a revisit and its relevance to oral/periodontal health. J. Periodontal Res. 2014; 49: 1–9.
11. Heumann D. CD14 and LBP in endotoxemia and infections caused by Gram-negative bacteria. J. Endotoxin Res. 2001; 7: 439–441.
12. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094–1104.
13. Jin CJ, Sellmann C, Engstler AJ, Ziegenhardt D, Bergheim I. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). Br. J. Nutr. 2015; 114: 1745–1755.
14. Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab. Invest. 2012; 92: 1020–1032.
15. Sellmann C, Jin CJ, Degen C, De Bandt JP, Bergheim I. Oral glutamine supplementation protects female mice from nonalcoholic steatohepatitis. J. Nutr. 2015; 145: 2280–2286.
16. Landmann M, Wagnerberger S, Kanuri G, Ziegenhardt D, Bergheim I. Beer is less harmful for the liver than plain ethanol: studies in male mice using a binge-drinking model. Alcohol Alcohol. 2015; 50: 493–500.
17. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810–820.
18. Sharifnia T, Antoun J, Verriere TG et al. Hepatic TLR4 signaling in obese NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 2015; 309: G270–G278.
19. Miele L, Marrone G, Lauritano C et al. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr. Pharm. Des. 2013; 19: 5314–5324.
20. Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin. Biochem. 2015; 48: 923–930.
21. Su L, Wang JH, Cong X et al. Intestinal immune barrier integrity in rats with nonalcoholic hepatic steatosis and steatohepatitis. Chin Med J (Engl) 2012; 125: 306–311.
22. Sellmann C, Priebs J, Landmann M et al. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. J. Nutr. Biochem. 2015; 26: 1183–1192.
23. Bergheim I, Weber S, Vos M et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J. Hepatol. 2008; 48: 983–992.
24. Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470–1481.
25. Rivera CA, Adegboyega P, van RN, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571–579.
26. Cobbold JF, Anstee QM, Goldin RD et al. Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clin.Sci.(Lond) 2009; 116: 403–413.
27. Farrell GC, Mridha AR, Yeh MM et al. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype. Liver Int. 2014; 34: 1084–1093.
28. Moreno-Navarrete JM, Ortega F, Serino M et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int. J. Obes. (Lond) 2012; 36: 1442–1449.
29. Tilves CM, Zmuda JM, Kuipers AL et al. Association of lipopolysaccharide-binding protein with aging-related adiposity change and prediabetes among African ancestry men. Diabetes Care 2016; 39: 385–391.
30. Zhu Q, Zhou H, Zhang A et al. Serum LBP is associated with insulin resistance in women with PCOS. PLoS One 2016; 11: e0145337.
31. Moreno-Navarrete JM, Escote X, Ortega F et al. Lipopolysaccharide binding protein is an adipokine involved in the resilience of the mouse adipocyte to inflammation. Diabetologia 2015; 58: 2424–2434.
32. Kawai T, Takeuchi O, Fujita T et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 2001; 167: 5887–5894.
33. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol. 2005; 26: 469–476.
34. Brown J, Wang H, Hajishengallis GN, Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J. Dent. Res. 2011; 90: 417–427.
35. Wagnerberger S, Spruss A, Kanuri G et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br. J. Nutr. 2012; 107: 1727–1738.
36. Ye D, Li FY, Lam KS et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012; 61: 1058–1067.
37. Reichold A, Brenner SA, Spruss A, Forster-Fromme K, Bergheim I, Bischoff SC. Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J. Nutr. Biochem. 2014; 25: 118–125.
38. Spruss A, Kanuri G, Uebel K, Bischoff SC, Bergheim I. Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid. Redox Signal. 2011; 14: 2121–2135.
39. Ying HZ, Liu YH, Yu B, Wang ZY, Zang JN, Yu CH. Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem. Toxicol. 2013; 52: 53–60.
40. Esposito E, Iacono A, Bianco G et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J. Nutr. 2009; 139: 905–911.
41. Wu X, Qian G, Zhao Y, Xu D. LBP inhibitory peptide reduces endotoxin-induced macrophage activation and mortality. Inflamm. Res. 2005; 54: 451–457.